Several neurodegenerative diseases are outstanding candidates for NRF2-targeted therapies such as AD, Parkinson’s disease, ALS disease, frontal and temporal lobes affecting frontotemporal dementia disease, autosomal recessive inherited disorder—Friedreich’s ataxia, fatal genetic disorder, HD and progressive debilitating prion diseases. Here, NFE2L2 is linked to neurodegenerative disease.